Profiel
Christopher Pierce worked as Senior Director-Hematologic Malignancies Portfolio at Pfizer Inc. from 2016 to 2017.
He then worked as Vice President & Head-Commercial at Loxo Oncology, Inc. from 2017 to 2019.
In 2019, he worked as Principal at Scout Advisers LLC.
In 2020, he worked as Chief Business Operations & Executive VP at Prelude Therapeutics, Inc. Mr. Pierce holds an MBA from Harvard Business School and an undergraduate degree from Harvard College.
Eerdere bekende functies van Christopher Pierce
| Bedrijven | Functie | Einde |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Corporate Officer/Principal | 30-09-2021 |
| Scout Advisers LLC | Corporate Officer/Principal | 01-07-2020 |
| LOXO ONCOLOGY INC | Corporate Officer/Principal | 01-05-2019 |
| PFIZER, INC. | Corporate Officer/Principal | 01-03-2017 |
Opleiding van Christopher Pierce
| Harvard College | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
| PFIZER, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| Scout Advisers LLC | |
Loxo Oncology, Inc.
 Loxo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT. | Health Technology |
